KOSDAQIT & Software040350

CreoSG

₩2,085▲ 2.96%2026-11-18 close
Market Cap
₩41.4B
Turnover
₩100M
Volume
50K
Shares out.
19.9M
PER
—
PBR
0.8×
EPS
-₩148
Dividend Yield
0.00%

PER, EPS, PBR and BPS are calculated in-house from the last 4 quarters (2025Q4–2026Q3) · Dividend yield is based on ₩0 per share · Prices as of the 2026-11-18 close

01

Report overview

Finance IT Orders Against Persistent Operating Losses

Revenue leans on bank IT solution orders, but four straight years of operating losses and funding transactions with the largest shareholder remain the key items to track.

  1. 1

    2025 revenue rose 33.1% year on year to KRW 10.9 billion, while the operating loss widened to KRW 6.41 billion.

  2. 2

    Operating losses ran for four consecutive years through 2025, and the 2Q 2026 operating loss of KRW 137 million was the smallest of the last five quarters.

  3. 3

    As of 3Q 2025, 90.8% of sales came from the solutions business, while the bio business reported no revenue.

  4. 4

    In April 2026 the company lent about KRW 6.3 billion to its largest shareholder, and in October 2026 it decided to acquire about KRW 8.1 billion of that shareholder's shares.

  5. 5

    PER is not calculated because the company posted net losses over the last four quarters, and the price-to-book ratio is below 1x.

02

Business structure

CreoSG listed on KOSDAQ on January 10, 2002, and its main businesses are financial IT solutions and bio drug development. As of the end of 3Q 2025, the solutions segment accounted for 90.8% of sales and the real estate operating subsidiary for 9.2%, and the bio business reported no revenue.

The solutions business supplies, implements and consults on the BANCS-K package, which provides framework and core banking functions to financial and public institutions. Banks are the prominent buyers, with recent projects including ICT rebuild work for one major Korean bank and a system build for another.

A supply contract with Samsung SDS disclosed on May 22, 2026 is worth KRW 1.99 billion and combines a product contract with a subcontract.

The contract period runs from May 26, 2026 to August 25, 2027, and the subcontract portion is larger than the product portion, which shows the company performing work under large IT contractors. The bio business centers on SUV-MAP, a recombinant VSV-based vaccine platform.

The company internalized the platform through a 2024 merger with a subsidiary and is pursuing vaccine development for COVID-19, MERS and other infectious diseases, along with clinical development of the AIDS vaccine candidate SAV001.

The company is also reviewing extending SUV-MAP into oncolytic virus and immuno-oncology applications. A real estate subsidiary handles leasing and management.

03

Earnings trend

Quarterly revenue · Operating profit
RevenueOperating profit
Annual revenue · Operating profit
RevenueOperating profit
Quarterly results · Last 5 quarters
QuarterRevenueOperating profitOp. margin
2025Q3₩2.9B-₩900M−31.9%
2025Q4₩3.2B-₩1.9B−60.2%
2026Q1₩2.6B-₩800M−30.9%
2026Q2₩3.2B-₩100M−4.3%
2026Q3₩2.6B-₩700M−26.3%
Annual results
YearRevenueOperating profitNet income (parent)Op. marginROEDebt-to-equity
2022₩9.8B-₩6.1B-₩10.4B−62.8%−27.0%91.0%
2023₩9.8B-₩3.7B-₩11.7B−38.3%−32.7%66.5%
2024₩8.2B-₩5.7B-₩12.5B−69.3%−24.8%81.6%
2025₩10.9B-₩6.4B-₩8.5B−59.0%−18.0%88.3%

Consolidated basis (financial statements including subsidiaries) · Final figures from DART filings · Net income attributable to owners of the parent · Data as of 2026-11-18

04

Earnings analysis

Annual revenue moved from KRW 9.78 billion in 2022 to KRW 9.76 billion in 2023 (down 0.3% year on year) and KRW 8.16 billion in 2024 (down 16.4%), before rising to KRW 10.9 billion in 2025 (up 33.1%). Among 2022 to 2025, 2025 was the largest year and 2024 the smallest.

The company attributed the 2025 revenue increase to higher sales at its solutions division and consolidated subsidiaries. The operating loss in 2025 was KRW 6.41 billion, wider than the KRW 5.65 billion loss in 2024.

Operating losses were KRW 6.14 billion in 2022, KRW 3.73 billion in 2023, KRW 5.65 billion in 2024 and KRW 6.41 billion in 2025, so the company has posted operating losses in each of the four years.

Operating margins were -62.8% in 2022, -38.3% in 2023, -69.3% in 2024 and -59.0% in 2025, with 2023 the smallest loss ratio. Net loss attributable to controlling shareholders was KRW 10.4 billion in 2022, KRW 11.7 billion in 2023 and KRW 12.5 billion in 2024, before narrowing to KRW 8.54 billion in 2025.

The company said the 2025 narrowing reflected a gain on convertible bonds it held and lower equity-method losses. The debt-to-equity ratio fell from 91.0% in 2022 to 66.5% in 2023, then rose to 81.6% in 2024 and 88.3% in 2025.

Operating cash flow was negative in all four years, from -KRW 4.2 billion in 2022 to -KRW 2.82 billion in 2025.

On a quarterly basis, the operating loss was KRW 922 million in 3Q 2025, KRW 1.94 billion in 4Q 2025, KRW 812 million in 1Q 2026, KRW 137 million in 2Q 2026 and KRW 692 million in 3Q 2026, which is five straight quarters of losses.

Sales in 2Q 2026 were KRW 3.18 billion, up 20.9% from the prior quarter, and net income attributable to controlling shareholders turned positive at KRW 1.79 billion. A profit despite a small operating loss points to non-operating or tax items, and their breakdown can be checked in the quarterly report.

Sales in 3Q 2026 were KRW 2.64 billion, down 8.6% year on year, and the controlling-shareholder net loss of KRW 637 million was smaller than a year earlier. The controlling-shareholder net loss over the last four quarters totaled KRW 2.9 billion.

05

Industry analysis

In the 2025 annual comparison compiled by AlphaSquare, CreoSG ranked 94th of 100 IT services companies on sales and 93rd on operating margin. The same comparison put the sector average operating margin at -7.90%, well above the company's loss ratio.

Its debt-to-equity ratio ranked 36th in the same group and sat below the sector average. Bank IT infrastructure is one pillar of demand, with a May 2026 Woori Bank infrastructure optimization project as a representative case in which Samsung SDS acted as the prime contractor.

The contract end date is an expected date tied to payment collection, and the company said any change would be followed by a corrective disclosure. On the bio side, the sector narrative is tied to cancer vaccines and immuno-oncology.

In August 2026 Moderna and Merck reported that a phase 3 trial of a personalized cancer vaccine met its primary endpoints, and the company framed this as evidence that vaccine-based immune platforms can extend to oncology. The SUV-MAP platform can carry different antigen genes to address different diseases.

The company obtained a domestic COVID-19 vaccine patent in October 2026 and holds MERS vaccine patents in Saudi Arabia and Canada. Its vaccine push targets countries with high demand for specific infectious diseases, making overseas demand a key variable.

Domestic IT investment demand and the clinical stage of bio candidates follow different cycles, so the two businesses' contributions tend to move separately.

06

Outlook

The supply contract with Samsung SDS was disclosed as running from May 26, 2026 to August 25, 2027. The company said the end date is an expected date tied to payment collection after delivery.

In IT solutions, projects such as the ICT rebuild for one major Korean bank and a system build for another remain the base of solutions sales. On the bio side, the company said its October 2026 domestic patent for a COVID-19 vaccine broadened the platform's intellectual property.

The company is reviewing extending SUV-MAP into oncolytic virus and immuno-oncology applications. In September 2026 the CEO said the goal is to develop an immuno-oncology drug usable on its own, and that co-development with multinational pharmaceutical companies or technology licensing remains open.

The vaccine push targets countries with high demand for specific infectious diseases. The company's medium-term strategy is to develop SUV-MAP into a general-purpose rVSV platform not limited to specific infectious diseases.

On the financial side, the loan to the largest shareholder carries a 6% rate, a three-year term running to April 9, 2029, and a total balance of KRW 9.15 billion. The next checkpoints are the full-year operating loss and cash flow in the 2026 annual report, and the revenue progress on the Samsung SDS contract.

07

Valuation

PER
—
PBR
0.8×
ROE
-6.2%
EPS
-₩148
BPS
₩2,420
Dividend per share
₩0

PER is not calculated because the company has posted net losses attributable to controlling shareholders over the last four quarters. The price-to-book ratio sits below 1x, meaning the shares trade below book value per share. The company pays no dividend, so its dividend yield is well below the sector average.

Against the sector average shown in the AlphaSquare comparison, the company's operating margin ranks near the bottom, while its debt-to-equity ratio is below the sector average.

The company has recorded losses for four consecutive years and cut its capital in 2025 to cover accumulated deficits, which is a starting point for reading its capital structure. A price below book value alongside a record of operating losses leaves open whether the market weighs asset value or earnings more heavily.

With PER unavailable, price-to-book and the trend in operating results are the most direct points of comparison.

PER, EPS, PBR and BPS are all calculated in-house (the same method as Naver and Toss) · Dividend yield = cash dividend per share from DART filings (supplemented by KRX) ÷ current price · As of 2026-11-18

08

Bull factors

Bank IT order base

A supply contract with Samsung SDS equals 18.32% of 2025 revenue, according to the disclosure. Bank projects support the solutions business, and the company credited higher solutions and subsidiary sales for the 2025 revenue increase.

Narrowing quarterly operating losses

The operating loss narrowed from KRW 812 million in 1Q 2026 to KRW 137 million in 2Q 2026, and net income attributable to controlling shareholders turned positive in 2Q. The 3Q 2026 operating loss of KRW 692 million was smaller than the KRW 1.94 billion loss of 4Q 2025.

Platform extension potential

SUV-MAP can be applied to different diseases by changing the carried gene, and a domestic COVID-19 vaccine patent supports the platform. The company is reviewing extending the platform into immuno-oncology.

09

Bear factors

Four straight years of operating losses

The operating loss persisted for four consecutive years, and the 2025 loss of KRW 6.41 billion was larger than the KRW 5.65 billion loss in 2024. The 2025 operating margin of -59.0% ranks near the bottom of the sector comparison.

Capital structure history

The company decided a 2-for-1 capital reduction in October 2025 after its capital erosion ratio rose to 53.0% at mid-2025, which led to a caution designation. In June 2026 it was released from a warning designation and placed on a one-day caution list, with a possible re-designation notice.

Related-party funding

In April 2026 the company lent about KRW 6.3 billion to its largest shareholder for a convertible bond conversion, and the disclosure said no actual cash outflow would occur. In October 2026 it decided to acquire about KRW 8.1 billion of that shareholder's shares, equal to 17.14% of equity.

10

Risk factors

Financial and capital structure

Operating cash flow was negative in all four years through 2025, although the outflow narrowed to KRW 2.82 billion in 2025. Total liabilities stood at KRW 41.7 billion at the end of 2025, a large share of total assets, and the company cut capital in 2025 to cover deficits.

Related-party transactions

The loan balance to the largest shareholder totals KRW 9.15 billion, and the October 2026 share acquisition equals 17.14% of equity. Because these related-party amounts are large relative to equity, loan terms and recovery could affect the financial picture.

Bio commercialization and share price volatility

The bio business reported no revenue as of 3Q 2025, and the AIDS vaccine candidate SAV001 is still in clinical development, so commercialization timing is uncertain. The share price has also been volatile, including a trading halt tied to a share consolidation that took effect in April 2026.

11

What to watch next

  1. March 2027

    Filing of the 2026 annual report, which will show full-year 2026 sales, operating loss and net income attributable to controlling shareholders, including 4Q 2026. The 2025 annual report was filed on March 16, 2026.

  2. Mid-May 2027

    Filing of the 1Q 2027 quarterly report, where the shareholder loan balance, interest income and non-operating items can be checked.

  3. August 25, 2027

    Expected end date of the IT infrastructure supply contract with Samsung SDS, where revenue progress and any corrective disclosure can be checked.

  4. April 9, 2029

    End of the loan term to the largest shareholder, where conversion or repayment status can be confirmed.

12

Overall view

CreoSG is a KOSDAQ company that pairs financial IT solutions with a vaccine and immuno-oncology platform, and most of its sales come from the solutions business. Revenue rose 33.1% to KRW 10.9 billion in 2025, but the operating loss widened to KRW 6.41 billion, extending four straight years of operating losses.

Quarterly operating losses narrowed to KRW 137 million in 2Q 2026 and KRW 692 million in 3Q 2026, but 3Q 2026 sales fell 8.6% year on year. Net income attributable to controlling shareholders turned positive at KRW 1.79 billion in 2Q 2026 and returned to a KRW 637 million loss in 3Q 2026.

Strengths include contracts with large IT groups including Samsung SDS, bank projects, and patents and possible extensions of the SUV-MAP platform.

Weaknesses include the accumulated losses and capital history, the size of funding transactions with the largest shareholder, and the uncertain timing of commercialization in the bio business, which has no revenue.

PER is not calculated and the price-to-book ratio is below 1x, so valuation highlights the gap between net assets and operating performance.

The next checkpoints are the full-year operating loss and cash flow in the 2026 annual report, the repayment status of the related-party loan, and the revenue progress of the Samsung SDS contract. This report is for information only and includes no buy or sell opinion or target price.

13

Sources

  1. Korea Exchange (KRX) — Prices · Market Cap · Volume
  2. FSS electronic disclosure system (DART) — Financial statements · Dividend filings
Show 18 more articles and sources
  1. comp.wisereport.co.kr
  2. news.nate.com
  3. comp.fnguide.com
  4. creosg.com
  5. alphasquare.co.kr
  6. kind.krx.co.kr
  7. core.asiae.co.kr
  8. view.asiae.co.kr
  9. digitaltoday.co.kr
  10. akground.com
  11. news.nate.com
  12. m.news.nate.com
  13. m.news.nate.com
  14. m.news.nate.com
  15. digitaltoday.co.kr
  16. m.news.nate.com
  17. supple.kr
  18. topstarnews.net

Report written 2026-11-18 · Data as of 2026-11-17

This content is AI analysis of market data and web search results, provided for information only. It is not a solicitation or recommendation to invest. Investment decisions and their consequences are the investor's own responsibility. Data may be delayed or contain errors.

Other reports in this industry

View industry analysis